Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5582/irdr.2016.01045 http://scihub22266oqcxt.onion/10.5582/irdr.2016.01045 C4995416!4995416!27672538     free     free     free       Intractable+Rare+Dis+Res 2016 ; 5 (3): 158-67 Nephropedia Template TP {{tp|p=27672538|t=2016. Review of targeted treatments in fragile X syndrome |pdf=|usr=}}{{27672538}} gab.com Text Review of targeted treatments in fragile X syndrome JO: Intractable Rare Dis Res http://www.kidney.de/pget.php?&tw=1&pmid=27672538 #FOAvip Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well. Twit Text FOAVip Review of targeted treatments in fragile X syndrome ????Intractable Rare Dis Res http://www.kidney.de/pget.php?&tw=1&pmid=27672538 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27672538 #FOAvip English Wikipedia <ref>{{Cite pmid|27672538}}</ref> Review of targeted treatments in fragile X syndrome #MMPMID27672538 Ligsay A; Hagerman RJ Intractable Rare Dis Res 2016[Aug]; 5 (3): 158-67 PMID27672538show ga Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well. äReview of targeted treatments in fragile X syndrome (epmc).pdf DeepDyve Pubget Overpricing